BVI's FineVision HP trifocal IOL, approved by the FDA, enhances the US premium IOL market with advanced optic design for multifocal vision correction. The lens features a diffractive optic design and ...

The AAOP's new training platform, developed with Alchemy Vision, enhances practice efficiency and patient care through ...

Epion Therapeutics announced that the United States Food and Drug Administration (FDA) has granted Fast Track designation to ...

The US Food and Drug Administration (FDA) has selected Abeona Therapeutics’ ABO-503 gene therapy for X-linked retinoschisis ...

Pediatric progressive myopia is a growing global public health concern, linked to serious ocular complications including ...

Beacon Therapeutics reports positive phase 2 results for gene therapy in X-linked retinitis pigmentosa ...

Tadayoni is professor of ophthalmology at Université de Paris in France and head of department at Lariboisière, Saint Louis and Adolphe de Rothschild Foundation hospitals. He is a European Society of ...

Michaelides is professor at UCL Institute of Ophthalmology and Moorfields Eye Hospital, London.

The Polaris platform is the world’s first AI-supported and robotics-enabled surgical system developed specifically for ...

The Eye Care Network caught up with Inder Paul Singh, MD, president of The Eye Centers of Racine and Kenosha in Wisconsin and founding medical advisor for Alchemy Vision, to learn more about the ...

The US Food and Drug Administration (FDA) has approved Celltrion’s aflibercept-boav (EYDENZELT) biosimilar referencing ...

Considering this knowledge of the retina, the investigators conducted a study in which the goals were to detect and quantify ...